About this Research Topic
Every 40s someone dies by suicide and for every person who completes a suicide, 20 or more may attempt to end their lives (WHO).
Severe mental illness and substance use disorders or their comorbidity are among the most relevant risk factors for suicide.
This Frontiers in Neuropharmacology Research Topic aims to improve education on the hot and sensitive topics of severe mental illness in comorbidity or not with substance use disorders and suicide ideation and raises awareness that these are preventable by addressing pharmacological interventions that could reduce the risk of suicide ideation among individuals suffering of a severe mental illness and/or substance use disorders.
This article collection will welcome (but it’s not limited to) the following topics:
• Suicide risk associated with substance use disorder and prevention
• Suicide risk assessment and intervention in people with mental illness
• Suicidality risk and medications/opioids treatments
• Antidepressant medications and strategy for managing treatment-resistant depression
• Molecular pathways associated with severe mental illness and suicidal ideation (ie: ketamine and mTOR signaling, Kynurenine Pathway, Therapy With Minocycline in Patients With Treatment-Resistant Depression, ketamine)
• Sleep, antidepressants and anti-suicidal improvements
• Pharmacological treatment that affects suicide (ie: Lithium and clozapine)
Severe mental illness and substance use disorders or their comorbidity are among the most relevant risk factors for suicide.
This Frontiers in Neuropharmacology Research Topic aims to improve education on the hot and sensitive topics of severe mental illness in comorbidity or not with substance use disorders and suicide ideation and raises awareness that these are preventable by addressing pharmacological interventions that could reduce the risk of suicide ideation among individuals suffering of a severe mental illness and/or substance use disorders.
This article collection will welcome (but it’s not limited to) the following topics:
• Suicide risk associated with substance use disorder and prevention
• Suicide risk assessment and intervention in people with mental illness
• Suicidality risk and medications/opioids treatments
• Antidepressant medications and strategy for managing treatment-resistant depression
• Molecular pathways associated with severe mental illness and suicidal ideation (ie: ketamine and mTOR signaling, Kynurenine Pathway, Therapy With Minocycline in Patients With Treatment-Resistant Depression, ketamine)
• Sleep, antidepressants and anti-suicidal improvements
• Pharmacological treatment that affects suicide (ie: Lithium and clozapine)
Keywords: suicide, suicide risk, suicide ideation, depression, treatment-resistant depression, substance use disorder, severe mental illness
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
